

In the Claims:

1. (Currently Amended) A co-crystal of mammalian Glucokinase (~~Seq ID NO:1~~) (SEQ ID NO:1) and a ligand bound to an allosteric site of the Glucokinase, wherein

the co-crystal has unit cell dimensions of:

a and b are from 79 Å to 80.2 Å;

c is from 318 Å to 325 Å;

α and β are 90°; and

γ is 120°;

and the co-crystal has P6(5)22 symmetry-, wherein further the ligand is selected from the group consisting of 3-Cyclopentyl-2-pyridin-4-yl-N-thiazol-2-yl-propionamide, N-(5-Bromo-pyridin-2-yl)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionamide, 2-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-trifluoromethyl-pyridin-2-yl)-propionamide, (2S)-2-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionylamino]-thiazole-4-carboxylic acid methyl ester, (2S)-{2-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionylamino]-thiazol-5-yl}-oxo-acetic acid ethyl ester, (2S)-{3-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionyl]-ureido}-acetic acid methylester, (2S)-1-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionyl]-3-(3-hydroxy-propyl)-urea, and (2S)-{3-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionyl]-ureido}-acetic acid ethyl ester.

2. (Currently Amended) A crystal of mammalian Glucokinase (~~Seq ID NO:1~~) (SEQ ID NO:1), wherein

the crystal has unit cell dimensions of:

a and b are from 79 Å to 80.2 Å;

c is from 318 Å to 325 Å;

α and β are 90°; and

γ is 120°;

and the crystal has P6(5)22 symmetry.

3. (Currently Amended) A process for co-crystalizing mammalian Glucokinase (~~Seq-ID NO:1~~) (SEQ ID NO:1) and an allosteric ligand of Glucokinase, the process comprising:

providing a buffered, aqueous solution of 9 to 22 mg/ml of the mammalian Glucokinase (SEQ ID NO:1);

adding a molar excess of the allosteric ligand to the aqueous solution of mammalian Glucokinase; and

growing crystals by vapor diffusion using a buffered reservoir solution of 16% to 25% PEG, 0% w/v to 30% w/v glucose and 8 to 10 mM DTT, wherein the PEG has an average molecular weight of about 8,000 to about 10,000-, wherein further the ligand is selected from the group consisting of 3-Cyclopentyl-2-pyridin-4-yl-N-thiazol-2-yl-propionamide, N-(5-Bromo-pyridin-2-yl)-2-(3-chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-propionamide, 2-(3-Chloro-4-methanesulfonyl-phenyl)-3-cyclopentyl-N-(5-trifluoromethyl-pyridin-2-yl)-propionamide, (2S)-2-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionylamino]-thiazole-4-carboxylic acid methyl ester, (2S)-{2-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionylamino]-thiazol-5-yl}-oxo-acetic acid ethyl ester, (2S)-{3-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionyl]-ureido}-acetic acid methylester, (2S)-1-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionyl]-3-(3-hydroxy-propyl)-urea, and (2S)-{3-[3-Cyclopentyl-2-(3,4-dichloro-phenyl)-propionyl]-ureido}-acetic acid ethyl ester.

4. (Currently Amended) The process of claim 3, wherein the step of growing crystals by vapor diffusion comprises:

streaking the buffered, aqueous solution of mammalian Glucokinase (~~Seq-ID NO:1~~) (SEQ ID NO:1) with added allosteric ligand on a surface to form an elongated droplet of protein solution, and

streaking about an equal amount of the buffered reservoir solution across the elongated droplet of protein solution, forming a combined droplet shaped like the letter 'X'.